2019 National Drug & Alcohol IQ Challenge

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

whitePaper | January 10, 2023

The ideal care model for complex patients is a model in which the entire health care team is made up of experts in the specific disease state being treated. Integrated health care systems and major academic medical centers provide this level of expertise and coordination.

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

whitePaper | November 10, 2022

We know people don’t like to be sold to. And in the so-called ‘attention economy’, it is more important than ever that your business can utilise meaningful marketing and advertising practices to engage with your customers and secure their attention.